Abstract
Nilotinib Vs. Dasatinib in Achieving MR4.5 for Newly Diagnosed Chronic Myeloid Leukemia: Results of the Prospective Randomized Phase 3 Study, JALSG CML212
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have